Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,261 across all filing types
Latest filing 2024-02-20 Board/Management Inform…
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we would like to inform you on the change in role of Mr. Amit Bhakri, currently the Business Unit Director - Biopharmaceutical ....
Board/Management Information Classification · 100% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) disclosing a change in the role of senior management personnel, specifically the appointment of Mr. Ayush Kumar Agarwal as Business Unit Director. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and includes an annexure with details about the appointment. There are no financial statements, earnings data, or detailed management discussion of financial results. The content is focused on management changes, not on financial performance or other report types. Therefore, this document fits the category of Board/Management Information (MANG). The document length is 3512 characters, which is relatively short and consistent with a management change announcement rather than a full report.
2024-02-20 English
Updates
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges (BSE and NSE) regarding a change in the role of senior management personnel within AstraZeneca Pharma India Limited. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30, which pertains to disclosures about changes in key managerial personnel. The content details the transition of Mr. Amit Bhakri and the appointment of Mr. Ayush Kumar Agarwal as Business Unit Director, including their roles, dates, and brief profiles. There are no financial statements, earnings data, or report attachments. The document is clearly an announcement about management changes rather than a full management report or annual report. Therefore, it fits the category of Board/Management Information (MANG). The document length is 3512 characters, which is consistent with a detailed announcement but not a full report.
2024-02-20 English
Pursuant to Regulation 39(3) and other applicable regulation of SEBI (LODR) Regulations, 2015, we would like to inform you that the Registrar and Share Transfer Agents of the Company, Integrated ....
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the loss of share certificates. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, specifically Regulation 39(3), which pertains to share certificate loss and related disclosures. The content is an announcement about a shareholder's lost share certificates and the company's intention to issue a Letter of Confirmation after formalities. There is no financial data, no report attached or referenced as being published, and no mention of financial results, management changes, or other report types. This fits the category of a Regulatory Filing (RNS) as it is a compliance-related announcement that does not fit into other specific categories like share issue, director dealings, or capital updates.
2024-02-12 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the loss of share certificates. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and informs about the loss of specific share certificates and the process to issue a Letter of Confirmation. There is no financial data, earnings information, or report attached or referenced as being published. The document is an official regulatory announcement related to share certificate loss, which does not fit into financial reports, earnings, or management information categories. It is best classified as a Regulatory Filing (RNS) because it is a compliance-related disclosure to stock exchanges that does not fit other specific categories.
2024-02-12 English
Copy of Newspaper Publication
Regulatory Filings
2024-02-12 English
Please find the enclosed Newspaper Publication of the Financial Results for the quarter ended December 31, 2023.
Regulatory Filings
2024-02-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.